全文获取类型
收费全文 | 114543篇 |
免费 | 9633篇 |
国内免费 | 302篇 |
专业分类
耳鼻咽喉 | 1376篇 |
儿科学 | 2979篇 |
妇产科学 | 1809篇 |
基础医学 | 15769篇 |
口腔科学 | 2199篇 |
临床医学 | 12446篇 |
内科学 | 24031篇 |
皮肤病学 | 1274篇 |
神经病学 | 10614篇 |
特种医学 | 4269篇 |
外国民族医学 | 2篇 |
外科学 | 17450篇 |
综合类 | 1796篇 |
一般理论 | 118篇 |
预防医学 | 9704篇 |
眼科学 | 2952篇 |
药学 | 8100篇 |
1篇 | |
中国医学 | 121篇 |
肿瘤学 | 7468篇 |
出版年
2023年 | 783篇 |
2022年 | 1243篇 |
2021年 | 2904篇 |
2020年 | 1659篇 |
2019年 | 2725篇 |
2018年 | 3088篇 |
2017年 | 2219篇 |
2016年 | 2340篇 |
2015年 | 2753篇 |
2014年 | 3962篇 |
2013年 | 5217篇 |
2012年 | 8072篇 |
2011年 | 8412篇 |
2010年 | 4579篇 |
2009年 | 4093篇 |
2008年 | 6869篇 |
2007年 | 7168篇 |
2006年 | 6626篇 |
2005年 | 6647篇 |
2004年 | 6022篇 |
2003年 | 5568篇 |
2002年 | 5151篇 |
2001年 | 1675篇 |
2000年 | 1539篇 |
1999年 | 1622篇 |
1998年 | 1155篇 |
1997年 | 891篇 |
1996年 | 825篇 |
1995年 | 750篇 |
1994年 | 724篇 |
1993年 | 715篇 |
1992年 | 1099篇 |
1991年 | 1030篇 |
1990年 | 1035篇 |
1989年 | 927篇 |
1988年 | 881篇 |
1987年 | 855篇 |
1986年 | 818篇 |
1985年 | 844篇 |
1984年 | 705篇 |
1983年 | 632篇 |
1982年 | 532篇 |
1981年 | 545篇 |
1980年 | 448篇 |
1979年 | 563篇 |
1978年 | 489篇 |
1977年 | 400篇 |
1976年 | 349篇 |
1974年 | 422篇 |
1973年 | 402篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
1.
2.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
3.
Triposkiadis Filippos Xanthopoulos Andrew Skoularigis John Starling Randall C. 《Heart failure reviews》2022,27(6):1991-2003
Heart Failure Reviews - The nitric oxide (NO)–guanylate cyclase (GC)–cyclic guanosine monophosphate (cGMP) pathway plays an important role in cardiovascular, pulmonary and renal... 相似文献
4.
Timothy J. Cordingley Mark A.G. Wilson Kathryn M. Weston 《Health & social care in the community》2022,30(1):353-359
Vaccination is a vital health care initiative to prevent individual and population infection. To increase vaccination rates the federal government implemented the ‘No Jab, No Pay’ policy, where eligibility for several government benefits required children to be fully vaccinated by removing ‘conscientious objections’ and expanding the age range of children whose families receive benefits. This study assesses the impact of this policy at a local area within a single medical practice community in NSW, Australia. A retrospective clinical audit was performed between 2012 and 2017 on a single general practice's vaccination records for children ≤19 years. Catch-up vaccinations were assessed based on age at vaccination. Incidence of catch-up vaccinations was assessed for each of four years before and two years after the implementation of the ‘No Jab, No Pay’ policy in January 2016, along with the age of children and vaccination(s) given. Catch-up vaccinations were assessed temporally either side of implementation of ‘No Jab, No Pay’. Comparing the average annual vaccination catch-up incidence rate of 6.2% pre-implementation (2012–2015), there was an increase to 9.2% in 2016 (p < .001) and 7.8% in 2017 (p = .027). Secondary outcome measurement of catch-up vaccination incidence rates before (2012–2015) and after (2016–2017) ‘No Jab, No Pay’ implementation showed statistically significant increases for children aged 8–11 years (3.2%–5.6%, p = .038), 12–15 years (7.5%–14.7%, p < .001) and 16–19 years (3.3%–10.2%, p < .001) along with a statistically significant reduction in children aged 1–3 years (11.4%–6.2%, p = .015). Also, catch-up rates for DTPa significantly increased after program implementation. This study demonstrates that the Australian federal government vaccination policy ‘No Jab, No Pay’ was coincident with an increase in catch-up vaccinations within a rural NSW community served by one medical practice, especially for older children. 相似文献
5.
James A. Akingbasote Alison J. Foster Ian Wilson Sunil Sarda Huw B. Jones J. Gerry Kenna 《Archives of toxicology》2016,90(4):853-862
Hepatic NADPH-cytochrome P450 oxidoreductase null (HRN?) mice exhibit normal hepatic and extrahepatic biotransformation enzyme activities when compared to wild-type (WT) mice, but express no functional hepatic cytochrome P450 activities. When incubated in vitro with [14C]-diclofenac, liver microsomes from WT mice exhibited extensive biotransformation to oxidative and glucuronide metabolites and covalent binding to proteins was also observed. In contrast, whereas glucuronide conjugates and a quinone-imine metabolite were formed when [14C]-diclofenac was incubated with HRN? mouse liver, only small quantities of P450-derived oxidative metabolites were produced in these samples and covalent binding to proteins was not observed. Livers from vehicle-treated HRN? mice exhibited enhanced lipid accumulation, bile duct proliferation, hepatocellular degeneration and necrosis and inflammatory cell infiltration, which were not present in livers from WT mice. Elevated liver-derived alanine aminotransferase, glutamate dehydrogenase and alkaline phosphatase activities were also observed in plasma from HRN? mice. When treated orally with diclofenac for 7 days, at 30 mg/kg/day, the severities of the abnormal liver histopathology and plasma liver enzyme findings in HRN? mice were reduced markedly. Oral diclofenac administration did not alter the liver histopathology or elevate plasma enzyme activities of WT mice. These findings indicate that HRN? mice are valuable for exploration of the role played by hepatic P450s in drug biotransformation, but poorly suited to investigations of drug-induced liver toxicity. Nevertheless, studies in HRN? mice could provide novel insights into the role played by inflammation in liver injury and may aid the evaluation of new strategies for its treatment. 相似文献
6.
Rocha Déborah Ribeiro Nery Jaqueline Freire Furini Leonardo Negri Constantino Carlos José Leopoldo Eller Lizziane Kretli Winkelströter Nai Gisele Alborghetti Nakagaki Wilson Romero 《Lasers in medical science》2020,35(8):1703-1709
Lasers in Medical Science - Studies reported the harmful effects of 2,4-D on body tissues, provoking changes in the anatomy and physiology of the kidneys, liver, and testicles. Thus, the objective... 相似文献
7.
8.
9.
10.
William R. C. Knight Cara R. Baker Nyree Griffin Wahyu Wulaningsih Mark Kelly Andrew R. Davies James A. Gossage 《British journal of cancer》2021,124(10):1653
Background A high Mandard score implies a non-response to chemotherapy in oesophageal adenocarcinoma. However, some patients exhibit tumour volume reduction and a nodal response despite a high score. This study examines survival and recurrence patterns in these patients.Methods Clinicopathological factors were analysed using multivariable Cox regression assessing time to death and recurrence. Computed tomography-estimated tumour volume change was examined in a subgroup of consecutive patients.Results Five hundred and fifty-five patients were included. Median survival was 55 months (Mandard 1–3) and 21 months (Mandard 4 and 5). In the Mandard 4 and 5 group (332 patients), comparison between complete nodal responders and persistent nodal disease showed improved survival (90 vs 18 months), recurrence rates (locoregional 14.75 vs 28.74%, systemic 24.59 vs 48.42%) and circumferential resection margin positivity (22.95 vs 68.11%). Complete nodal response independently predicted improved survival (hazard ratio 0.34 (0.16–0.74). Post-chemotherapy tumour volume reduction was greater in patients with a complete nodal response (−16.3 vs −7.7 cm3, p = 0.033) with no significant difference between Mandard groups.Conclusion Patients with a complete nodal response to chemotherapy have significantly improved outcomes despite a poor Mandard score. High Mandard score does not correspond with a non-response to chemotherapy in all cases and patients with nodal downstaging may still benefit from adjuvant chemotherapy.Subject terms: Oesophageal cancer, Surgical oncology 相似文献